Overexpression of Membrane Proteins in Primary and Metastatic Gastrointestinal Neuroendocrine Tumors

[1] Yao JC(2008)One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States J Clin Oncol. 26 3063-3072

[2] Hassan M(2008)Gastroenteropancreatic neuroendocrine tumours Lancet Oncol. 9 61-72

[3] Phan A(2009)Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol. 27 4656-4663

[4] Modlin IM(2012)Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol. 23 vii124-30

[5] Oberg K(2012)Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study Endocr Relat Cancer. 19 657-666

[6] Chung DC(2012)Antitumor effects of somatostatin analogs in neuroendocrine tumors Oncologist. 17 747-755

[7] Rinke A(2003)The pathophysiological consequences of somatostatin receptor internalization and resistance Endocr Rev. 24 28-47

[8] Muller HH(1993)Somatostatin receptor scintigraphy with [ Eur J Nucl Med. 20 716-731

[9] Schade-Brittinger C(2007)In-DTPA- J Nucl Med. 48 508-518

[10] Oberg K(2013)-Phe1]- and [ Eur J Nucl Med Mol Imaging. 40 800-16

[1] Yao JC(2008)One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States J Clin Oncol. 26 3063-3072

[2] Hassan M(2008)Gastroenteropancreatic neuroendocrine tumours Lancet Oncol. 9 61-72

[3] Phan A(2009)Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol. 27 4656-4663

[4] Modlin IM(2012)Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol. 23 vii124-30

[5] Oberg K(2012)Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study Endocr Relat Cancer. 19 657-666

[6] Chung DC(2012)Antitumor effects of somatostatin analogs in neuroendocrine tumors Oncologist. 17 747-755

[7] Rinke A(2003)The pathophysiological consequences of somatostatin receptor internalization and resistance Endocr Rev. 24 28-47

[8] Muller HH(1993)Somatostatin receptor scintigraphy with [ Eur J Nucl Med. 20 716-731

[9] Schade-Brittinger C(2007)In-DTPA- J Nucl Med. 48 508-518

[10] Oberg K(2013)-Phe1]- and [ Eur J Nucl Med Mol Imaging. 40 800-16